Zhen Y, Yang Y, Zheng Y, Zheng Z, Zheng H, Tang S
bioRxiv. 2025; .
PMID: 39974915
PMC: 11838238.
DOI: 10.1101/2025.01.25.634845.
Sanchez-Valle J, Flores-Rodero M, Costa F, Carbonell-Caballero J, Nunez-Carpintero I, Tabares-Seisdedos R
bioRxiv. 2025; .
PMID: 39896586
PMC: 11785135.
DOI: 10.1101/2025.01.22.634077.
Rawani N, Chan A, Todd K, Baker G, Dursun S
Biomolecules. 2025; 15(1).
PMID: 39858403
PMC: 11761573.
DOI: 10.3390/biom15010010.
Akhmirov R, Mitiureva D, Zaichenko M, Smirnov K, Sysoeva O
Int J Mol Sci. 2025; 25(24.
PMID: 39769070
PMC: 11679555.
DOI: 10.3390/ijms252413305.
Senko D, Efimova O, Osetrova M, Anikanov N, Boyko M, Sharaev M
Schizophrenia (Heidelb). 2024; 10(1):123.
PMID: 39725684
PMC: 11671596.
DOI: 10.1038/s41537-024-00542-5.
Brain metabolic profiling of schizophrenia: a path towards a better understanding of the neuropathogenesis of psychosis.
Rossetti M, Stanca S, Panichi L, Bongioanni P
Metab Brain Dis. 2024; 40(1):28.
PMID: 39570439
DOI: 10.1007/s11011-024-01447-z.
Neurostructural changes in schizophrenia and treatment-resistance: a narrative review.
Paul T, See J, Vijayakumar V, Njideaka-Kevin T, Loh H, Lee V
Psychoradiology. 2024; 4:kkae015.
PMID: 39399446
PMC: 11467815.
DOI: 10.1093/psyrad/kkae015.
The Underlying Neurobiological Mechanisms of Psychosis: Focus on Neurotransmission Dysregulation, Neuroinflammation, Oxidative Stress, and Mitochondrial Dysfunction.
Rawani N, Chan A, Dursun S, Baker G
Antioxidants (Basel). 2024; 13(6).
PMID: 38929148
PMC: 11200831.
DOI: 10.3390/antiox13060709.
A multicenter, double-blind, randomized, controlled study of patients with treatment-resistant schizophrenia treated with yokukansan for 12 weeks.
Horiguchi J, Wake R, Murotani K, Seno H, Miyaoka T, Inoue K
PCN Rep. 2024; 2(4):e155.
PMID: 38868736
PMC: 11114414.
DOI: 10.1002/pcn5.155.
New clues for the role of cerebellum in schizophrenia and the associated cognitive impairment.
Faris P, Pischedda D, Palesi F, DAngelo E
Front Cell Neurosci. 2024; 18:1386583.
PMID: 38799988
PMC: 11116653.
DOI: 10.3389/fncel.2024.1386583.
Interaction of serotonin/GLP-1 circuitry in a dual preclinical model for psychiatric disorders and metabolic dysfunction.
Kolling L, Khan K, Wang R, Pierson S, Hartman B, Balasubramanian N
Psychiatry Res. 2024; 337:115951.
PMID: 38735240
PMC: 11267813.
DOI: 10.1016/j.psychres.2024.115951.
New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists.
Peng A, Chai J, Wu H, Bai B, Yang H, He W
Neuropsychiatr Dis Treat. 2024; 20:607-620.
PMID: 38525480
PMC: 10961082.
DOI: 10.2147/NDT.S455279.
Quetiapine improves sensorimotor gating deficit in a sleep deprivation-induced rat model.
Ozcan O, Cevreli B, Temizyurek A, Karahan M, Konuk M
Sleep Biol Rhythms. 2024; 22(2):269-278.
PMID: 38524169
PMC: 10959884.
DOI: 10.1007/s41105-023-00504-x.
Activity of Protein Kinase A in the Frontal Cortex in Schizophrenia.
Sahay S, Henkel N, Vargas C, McCullumsmith R, ODonovan S
Brain Sci. 2024; 14(1).
PMID: 38248228
PMC: 10813263.
DOI: 10.3390/brainsci14010013.
Techniques for Measurement of Serotonin: Implications in Neuropsychiatric Disorders and Advances in Absolute Value Recording Methods.
Rojas Cabrera J, Oesterle T, Rusheen A, Goyal A, Scheitler K, Mandybur I
ACS Chem Neurosci. 2023; 14(24):4264-4273.
PMID: 38019166
PMC: 10739614.
DOI: 10.1021/acschemneuro.3c00618.
The Gut-Brain Axis in Schizophrenia: The Implications of the Gut Microbiome and SCFA Production.
Ju S, Shin Y, Han S, Kwon J, Choi T, Kang I
Nutrients. 2023; 15(20).
PMID: 37892465
PMC: 10610543.
DOI: 10.3390/nu15204391.
Novel Compounds in the Treatment of Schizophrenia-A Selective Review.
Tsapakis E, Diakaki K, Miliaras A, Fountoulakis K
Brain Sci. 2023; 13(8).
PMID: 37626549
PMC: 10452918.
DOI: 10.3390/brainsci13081193.
Viral Infections and Schizophrenia: A Comprehensive Review.
Kotsiri I, Resta P, Spyrantis A, Panotopoulos C, Chaniotis D, Beloukas A
Viruses. 2023; 15(6).
PMID: 37376644
PMC: 10302918.
DOI: 10.3390/v15061345.
Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies.
Kositsyn Y, de Abreu M, Kolesnikova T, Lagunin A, Poroikov V, Harutyunyan H
Int J Mol Sci. 2023; 24(11).
PMID: 37298431
PMC: 10253480.
DOI: 10.3390/ijms24119482.
Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study.
Isaacson S, Goldstein M, Pahwa R, Singer C, Klos K, Pucci M
Neurol Clin Pract. 2023; 13(4):e200175.
PMID: 37273942
PMC: 10238151.
DOI: 10.1212/CPJ.0000000000200175.